ArticleBMC psychiatry2026
Association of serum BMP2 with delayed memory impairment in first-episode, drug-naïve schizophrenia.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCognitive impairments, particularly in the domain of memory, are core and enduring features of schizophrenia. Bone morphogenetic proteins (BMPs), members of the transforming growth factor-β superfamily, are involved in neurodevelopment and synaptic plasticity, but few studies have investigated their relevance to cognitive deficits in schizophrenia.
methodsIn this study, we measured circulating levels of BMP2, BMP9, and BMP10, and evaluated correlations with cognitive performance and psychopathological symptoms among first-episode, drug-naïve (FEDN) patients with schizophrenia. Ninety FEDN patients were assessed for psychiatric symptoms using the Positive and Negative Syndrome Scale (PANSS). Patients and ninety demographically matched healthy controls (HCs) also completed the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and provided serum samples for Luminex-based BMP assays.
resultsAfter covariate adjustment, patients exhibited significantly elevated serum BMP2 (p = 0.015) and BMP9 (p = 0.004) concentrations. Within the patient group, higher serum BMP2 was significantly negatively associated with RBANS delayed memory (RBANS-DM) scores after adjustment for demographic and clinical covariates (β = -0.236, p = 0.014), accounting for a modest 7% of variance (partial R
conclusionsThese results suggest a potential association between elevated serum BMP2 and poorer delayed memory performance in early-stage schizophrenia. Given the cross-sectional design and modest effect size, the findings should be interpreted as hypothesis-generating rather than causal. BMP2 may represent a candidate peripheral correlate of delayed memory performance, warranting replication in larger, longitudinal, multicenter studies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.